Mesenchymal Stromal Cell Committee

Charter

The Mesenchymal Stromal Cell Committee strives to:

  • Assist in the planning of the annual meeting scientific program and the review of submitted abstracts in the non-hematopoietic stem cell field.
  • Review the status of the MSC field and compile a list of major scientific issues that must be addressed to advance or enable cellular therapies utilizing MSCs.
  • Foster international discussion about controversies in the MSC field and method standardization.
  • Publish position papers and engage in scientific discourse as necessary to advance the field.

 

Publications

Perspectives of the International Society of Cell & Gene Therapy Gastrointestinal Scientific Committee on the Intravenous Use of Mesenchymal Stromal Cells in Inflammatory Bowel Disease (PeMeGi). (Cytotherapy. 2019 Jun 11; DOI: 10.1016/j.jcyt.2019.05.003)

 

Manufacturing mesenchymal stromal cells for clinical applications: A survey of Good Manufacturing Practices at U.S. academic centers. (Cytotherapy. 2019 Jun 7; 00:1-11)

 

Challenges for mesenchymal stromal cell therapies. (Sci Transl Med. 2019 Feb; 11(480))

Response to Nature commentary "Clean up this stem-cell mess. (Cytotherapy. 2019 Jan; 21(1):1-2)

Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities. Cell Stem Cell. 2018 Jun 1;22(6):824-833. doi: 10.1016/j.stem.2018.05.004. Review.

2017 MSC Trials (Members only)

A relativity concept in mesenchymal stromal cell manufacturing. (Cytotherapy 2016 May;18(5):613-20.)

International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. (Cytotherapy 2016 Feb;18(2):151-9.)

Immunological characterization of multipotent mesenchymal stromal cells--The International Society for Cellular Therapy (ISCT) working proposal. (Cytotherapy 2013 Sep;15(9):1054-61.)

MSCs: science and trials. (Nat Med. 2013 Jul;19(7):812.)

Mesenchymal stromal cells: misconceptions and evolving concepts. (Cytotherapy 2013 Feb;15(2):140-5.)

The mesenchymal stromal cells dilemma-does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? (Cytotherapy. 2013 Jan;15(1):2-8. doi: 10.1016/j.jcyt.2012.10.002.)

Limited acquisition of chromosomal aberrations in human adult mesenchymal stromal cells. (Cell Stem Cell. 2012 Jan 6;10(1):9-10; author reply 10-1.)

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement (Cytotherapy 2006, 8(4): 315-317)


 

Committee Members:

 

 

 
Jacques Galipeau, MD
Chair (June 2016- Present)
University of Wisconsin-Madison
Madison, WI, United States
Co-Chair, ISCT 2016 Annual Meeting

Mauro Krampera, MD
University of Verona
Verona, Italy

Katarina Le Blanc, MD, PhD
Karolinska University Hospital
Stockholm, Sweden
Co-Chair, ISCT 2017 MSC Series

Ivan Martin, PhD
University Hospital Basel
Basel, Switzerland
Co-Chair, ISCT 2020 Annual Meeting; Co-Chair, ISCT 2017 MSC Series

Jan Nolta, PhD
UC Davis - Stem Cell Program
Sacramento, CA, United States
Co-Chair, ISCT 2018 MSC Pre-Conference Track

Donald G. Phinney, PhD
The Scripps Research Institute - Scripps Florida
Jupiter, FL, United States
Co-Chair, ISCT 2018/2019 MSC Pre-Conference Track

Yufang Shi, PhD
Shanghai Institutes for Biological Sciences
Shanghai, China
Co-Chair, ISCT 2019 MSC Pre-Conference Track  

Luc Sensebé, MD, PhD
Establissement Francais Du Sang EFS
Toulouse, France
Co-Chair, ISCT 2014 Annual Meeting; MSC Committee Chair 2011 – 2016

Sowmya Viswanathan, PhD
University Health Network
Toronto, ON, Canada
ISCT Liason Officer to ISO/TC276


 

© 2019 ISCT. All rights reserved. 
ISCT, and the ISCT logo are registered trademarks of the International Society for Cellular Therapy.
The BEACON and lighthouse logo is a service mark of the International Society for Cellular Therapy.

ISCT Privacy Policy